DK0387867T3 - Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse - Google Patents

Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse

Info

Publication number
DK0387867T3
DK0387867T3 DK90104875.1T DK90104875T DK0387867T3 DK 0387867 T3 DK0387867 T3 DK 0387867T3 DK 90104875 T DK90104875 T DK 90104875T DK 0387867 T3 DK0387867 T3 DK 0387867T3
Authority
DK
Denmark
Prior art keywords
cycloserine
alanine
cognitive
treat
psychotic disorder
Prior art date
Application number
DK90104875.1T
Other languages
Danish (da)
English (en)
Inventor
Alexis A Cordi
Michael R Jans
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0387867T3 publication Critical patent/DK0387867T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicinal Preparation (AREA)
DK90104875.1T 1989-03-15 1990-03-15 Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse DK0387867T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (1)

Publication Number Publication Date
DK0387867T3 true DK0387867T3 (da) 1993-06-01

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90104875.1T DK0387867T3 (da) 1989-03-15 1990-03-15 Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse

Country Status (17)

Country Link
US (1) US5061721A (enExample)
EP (1) EP0387867B1 (enExample)
JP (1) JP2963720B2 (enExample)
KR (1) KR900013961A (enExample)
AT (1) ATE88890T1 (enExample)
AU (1) AU624917B2 (enExample)
CA (1) CA2010635C (enExample)
DE (1) DE69001503T2 (enExample)
DK (1) DK0387867T3 (enExample)
ES (1) ES2055197T3 (enExample)
FI (1) FI901289A7 (enExample)
GR (1) GR3008225T3 (enExample)
IE (1) IE64130B1 (enExample)
IL (1) IL93562A (enExample)
NO (1) NO901198L (enExample)
NZ (1) NZ232809A (enExample)
PT (1) PT93424B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
CA2159326C (en) * 1993-03-29 2000-05-30 Robert Kisilevsky Method for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
AU735389B2 (en) 1996-07-22 2001-07-05 Cognetix, Inc. Use of conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
DE69936848T2 (de) * 1998-04-14 2008-05-15 The General Hospital Corp., Boston Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
JP2004527520A (ja) 2001-04-02 2004-09-09 パノラマ リサーチ，インコーポレイティド 治療剤としての抗酸化ニトロキシドおよびニトロン
AU2002256422A1 (en) * 2001-05-02 2002-11-11 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
AU2003215522A1 (en) * 2002-03-15 2003-09-29 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
US20050014743A1 (en) * 2003-05-27 2005-01-20 Forest Laboratories, Inc. Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2534909A1 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
JP2007517049A (ja) 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
JP5607930B2 (ja) 2006-10-12 2014-10-15 ビーエイチアイ リミテッド パートナーシップ ３−アミノ−１−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
CA2826180C (en) 2011-01-31 2020-09-01 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) 2013-01-29 2021-12-09 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212487C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
JP6823083B2 (ja) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
KR102465757B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
EP4065109A4 (en) * 2019-11-27 2023-09-13 Neurorive Inc CYCLOSERINE AND LITHIUM COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
AU624917B2 (en) 1992-06-25
NO901198L (no) 1990-09-17
NO901198D0 (no) 1990-03-14
JPH03148221A (ja) 1991-06-25
JP2963720B2 (ja) 1999-10-18
KR900013961A (ko) 1990-10-22
EP0387867A1 (en) 1990-09-19
GR3008225T3 (enExample) 1993-09-30
CA2010635C (en) 2001-03-06
PT93424B (pt) 1996-08-30
DE69001503T2 (de) 1993-09-09
CA2010635A1 (en) 1990-09-15
ES2055197T3 (es) 1994-08-16
DE69001503D1 (de) 1993-06-09
FI901289A0 (fi) 1990-03-15
EP0387867B1 (en) 1993-05-05
IL93562A (en) 1996-01-31
IE900921L (en) 1990-09-15
PT93424A (pt) 1990-11-07
IE64130B1 (en) 1995-07-12
FI901289A7 (fi) 1990-09-16
IL93562A0 (en) 1990-11-29
US5061721A (en) 1991-10-29
ATE88890T1 (de) 1993-05-15
NZ232809A (en) 1992-05-26
AU5073490A (en) 1990-09-20

Similar Documents

Publication Publication Date Title
DK0387867T3 (da) Præparat indeholdende D-cycloserin og D-alanin til forbedring af hukommelse og indlæringsevne eller til behandling af en kognitiv eller psykotisk lidelse
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE59107331D1 (de) Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DE58904713D1 (de) Verwendung von zink- oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
FI850781A0 (fi) Foerfarande foer framstaellning av av l-karnitin pao mikrobiologiskt saett.
NO832554L (no) Middel for behandling av saar
HUT47427A (en) Bezafibrat for treating diabetes
DK327183D0 (da) Fremgangsmade til udfoerelse af elektromikrobiel reduktion
BR8904099A (pt) Processo para o tratamento de efluente contendo cianeto e/ou outras substancias oxidaveis e processo para controlar o teor de impurezas de cianeto oxidavel em um meio efluente aquoso ate um nivel aceitavel pelo meio ambiente
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DK0410430T3 (da) Fremgangsmåde til mikrobiologisk diskontinuerlig fremstilling af L-carnitin
DE3273177D1 (en) Trans-dihyldrolisuride antipsychotic
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
EP0092386A3 (en) Hydantoin therapeutic agents
FR2481702B1 (enExample)
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DK425886D0 (da) Oejengelsammensaetning og fremgangsmaade til behandling af oejeninfektioner
ATA408383A (de) Anlage zur biologischen sanierung von gewaessern durch zufuhr von sauerstoff
SE9103398D0 (sv) Use of potassium channel activators in the treatment of dysmenorrhea